Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SAVA

SAVA - Cassava Sciences Inc Stock Price, Fair Value and News

$2.04-0.08 (-3.77%)
Market Closed

58/100

SAVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

58/100

SAVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.54

Target 3M

$2.28

Target 6M

$2.37

SAVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SAVA Price Action

Last 7 days

-6.0%

Last 30 days

-2.4%

Last 90 days

-37.8%

Trailing 12 Months

-13.2%

SAVA RSI Chart

SAVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SAVA Valuation

Market Cap

98.5M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

56.88

EV/EBITDA

-4.16

Price/Free Cashflow

-1.18

SAVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.54

Target 3M

$2.28

Target 6M

$2.37

SAVA Fundamentals

SAVA Revenue

Revenue (TTM)

2.8M

SAVA Earnings

Earnings (TTM)

-106.0M

Earnings Growth (Yr)

61.32%

Earnings Growth (Qtr)

75.56%

SAVA Profitability

EBT Margin

-509.36%

Return on Equity

-129.99%

Return on Assets

-81.73%

Free Cashflow Yield

-85.08%

SAVA Investor Care

Shares Dilution (1Y)

0.41%

Diluted EPS (TTM)

-2.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202273.0K374.0K1.2M2.8M
202147.0K33.0K41.0K49.0K
2020308.0K241.0K166.0K112.0K
2019190.5K275.5K340.5K328.0K
201824.0K27.0K38.0K105.5K
201794.0K71.0K54.0K38.0K
201679.0K95.0K103.0K107.0K
201545.0K47.0K51.0K57.0K
201430.9M20.6M10.3M47.0K
20139.9M9.1M8.3M41.1M
201211.2M11.2M11.2M10.9M
201116.8M16.9M16.7M11.5M
2010019.3M18.1M16.8M
200900020.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cassava Sciences Inc

SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
 CEO
 WEBSITEcassavasciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

Cassava Sciences Inc Frequently Asked Questions

SAVA is the stock ticker symbol of Cassava Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Cassava Sciences Inc is 98.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SAVA's fair value in chart for subscribers.

The fair value guage provides a quick view whether SAVA is over valued or under valued. Whether Cassava Sciences Inc is cheap or expensive depends on the assumptions which impact Cassava Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SAVA.

As of Wed Jan 28 2026, SAVA's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 56.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SAVA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cassava Sciences Inc has provided -0.158 (multiply by 100 for percentage) rate of return.